ACE2 and COVID-19: Angiotensin-converting enzyme II (ACE2) has been found to be the human SARS-CoV-2 receptor, and since ACE2 is required for SARS-CoV-2 cell entrance, an ACE2-targeting method holds tremendous promise for the development of drugs to combat COVID-19.